Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIM: This study investigated the effect of repeated infusions of recombinant human erythropoietin (EPO) on markers of inflammation in patients with affective disorders and whether any changes in inflammatory markers were associated with improvements on verbal memory.

METHODS: In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (sub-study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS)⩽14) (sub-study 2). In both sub-studies, patients were randomised in a double-blind, parallel-group design to receive eight weekly intravenous infusions of EPO (Eprex; 40,000IU/ml) or saline (0.9% NaCl). Plasma concentrations of interleukin 6 (IL-6), interleukin 18 (IL-18) and high sensitive c-reactive protein (hsCRP) were measured at week 1 (baseline) and weeks 5, 9 and 14. HDRS-17 and neuropsychological function was assessed at weeks 1, 9 and 14 using a test battery including the RAVLT Auditory Verbal Learning Test (primary depression and primary cognition outcomes in the original trial).

RESULTS: EPO had no cumulative effect on plasma levels of IL-6 or IL-18 but increased hsCRP levels in patients with TRD (mean±SD change in ng/L: EPO: 0.43±1.64; Saline: -0.90±2.43; F(1,39)=4.78, p=0.04). EPO had no effects on inflammatory markers in BD. There was no correlation between change in inflammatory markers and change in verbal memory.

CONCLUSIONS: Repeated EPO infusions had no effect on IL-6 and IL-18 levels but produced a modest increase in hsCRP levels in patients with TRD. Changes over time in inflammatory markers were not correlated with changes in cognition suggesting that modulation of the inflammatory pathway is not a putative mechanism of the EPO-associated improvement of cognition in affective disorders.

OriginalsprogEngelsk
TidsskriftBrain, Behavior, and Immunity
Vol/bind57
Sider (fra-til)53-57
ISSN0889-1591
DOI
StatusUdgivet - 12 maj 2016

ID: 46481162